{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:45:20Z","timestamp":1793724320884,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00415-025-13217-7","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T14:01:27Z","timestamp":1751119287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-3884","authenticated-orcid":false,"given":"Marco","family":"Vercellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marasciulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rolando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Garelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Morana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"issue":"6","key":"13217_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/1352458515599246","volume":"22","author":"C Zecca","year":"2016","unstructured":"Zecca C, Disanto G, Sormani MP, Riccitelli GC, Cianfoni A, Del Grande F, Pravat\u00e0 E, Gobbi C (2016) Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler 22(6):782\u2013791. https:\/\/doi.org\/10.1177\/1352458515599246","journal-title":"Mult Scler"},{"issue":"12","key":"13217_CR2","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1177\/1352458518778010","volume":"24","author":"R Cortese","year":"2018","unstructured":"Cortese R, Ciccarelli O (2018) Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes. Mult Scler 24(12):1536\u20131537. https:\/\/doi.org\/10.1177\/1352458518778010","journal-title":"Mult Scler"},{"issue":"12","key":"13217_CR3","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1007\/s00415-019-09526-3","volume":"266","author":"F Granella","year":"2019","unstructured":"Granella F, Tsantes E, Graziuso S, Bazzurri V, Crisi G, Curti E (2019) Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey. J Neurol 266(12):3031\u20133037. https:\/\/doi.org\/10.1007\/s00415-019-09526-3","journal-title":"J Neurol"},{"issue":"6","key":"13217_CR4","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-021-10901-2","volume":"269","author":"E Di Sabatino","year":"2022","unstructured":"Di Sabatino E, Gaetani L, Sperandei S, Fiacca A, Guercini G, Parnetti L, Di Filippo M (2022) The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. J Neurol 269(6):3129\u20133135. https:\/\/doi.org\/10.1007\/s00415-021-10901-2","journal-title":"J Neurol"},{"issue":"10","key":"13217_CR5","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00415-023-11829-5","volume":"270","author":"S Ruggieri","year":"2023","unstructured":"Ruggieri S, Prosperini L, Petracca M, Logoteta A, Tinelli E, De Giglio L, Ciccarelli O, Gasperini C, Pozzilli C (2023) The added value of spinal cord lesions to disability accrual in multiple sclerosis. J Neurol 270(10):4995\u20135003. https:\/\/doi.org\/10.1007\/s00415-023-11829-5","journal-title":"J Neurol"},{"issue":"462","key":"13217_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123057","volume":"15","author":"L Lorefice","year":"2024","unstructured":"Lorefice L, Piras C, Sechi V, Barracciu MA, Cocco E, Fenu G (2024) Spinal cord MRI activity in multiple sclerosis: Predictive value for relapses and impact on treatment decisions. J Neurol Sci 15(462):123057. https:\/\/doi.org\/10.1016\/j.jns.2024.123057","journal-title":"J Neurol Sci"},{"issue":"5","key":"13217_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1177\/1352458516663034","volume":"23","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Altmann DR, Alves Da Mota P, Swanton JK, Miszkiel KA, Wheeler-Kingshott CG, Ciccarelli O, Miller DH (2017) Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler 23(5):665\u2013674. https:\/\/doi.org\/10.1177\/1352458516663034","journal-title":"Mult Scler"},{"issue":"3","key":"13217_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jcm10030463","volume":"10","author":"C Ostini","year":"2021","unstructured":"Ostini C, Bovis F, Disanto G, Ripellino P, Pravat\u00e0 E, Sacco R, Padlina G, Sormani MP, Gobbi C, Zecca C (2021) Recurrence and prognostic value of asymptomatic spinal cord lesions in multiple sclerosis. J Clin Med 10(3):463. https:\/\/doi.org\/10.3390\/jcm10030463","journal-title":"J Clin Med"},{"key":"13217_CR9","doi-asserted-by":"publisher","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, Fazekas F, Filippi M, Frederiksen J, Gasperini C, Hacohen Y, Kappos L, Li DKB, Mankad K, Montalban X, Newsome SD, Oh J, Palace J, Rocca MA, Sastre-Garriga J, Tintor\u00e9 M, Traboulsee A, Vrenken H, Yousry T, Barkhof F, Rovira \u00c0; Magnetic Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653\u2013670. https:\/\/doi.org\/10.1016\/S1474-4422(21)00095-8.","DOI":"10.1016\/S1474-4422(21)00095-8"},{"issue":"3","key":"13217_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS (2017) ORATORIO clinical investigators ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"key":"13217_CR11","doi-asserted-by":"publisher","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstr\u00f6m E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263\u20131273. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6.","DOI":"10.1016\/S0140-6736(18)30475-6"},{"issue":"9","key":"13217_CR12","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1007\/s00415-022-11166-z","volume":"269","author":"R Gold","year":"2022","unstructured":"Gold R, Piani-Meier D, Kappos L, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, Cree BAC (2022) Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. J Neurol 269(9):5093\u20135104. https:\/\/doi.org\/10.1007\/s00415-022-11166-z","journal-title":"J Neurol"},{"key":"13217_CR13","doi-asserted-by":"publisher","unstructured":"Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009 Oct;66(4):460\u201371. https:\/\/doi.org\/10.1002\/ana.21867.","DOI":"10.1002\/ana.21867"},{"issue":"1","key":"13217_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ene.15593","volume":"30","author":"C Pozzilli","year":"2023","unstructured":"Pozzilli C, Pugliatti M, Vermersch P, Grigoriadis N, Alkhawajah M, Airas L, Oreja-Guevara C (2023) Diagnosis and treatment of progressive multiple sclerosis: A position paper. Eur J Neurol 30(1):9\u201321. https:\/\/doi.org\/10.1111\/ene.15593. (Epub 2022 Oct 25)","journal-title":"Eur J Neurol"},{"issue":"8","key":"13217_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","volume":"97","author":"BAC Cree","year":"2021","unstructured":"Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, Murphy N, Lassmann H (2021) Secondary Progressive Multiple Sclerosis: New Insights. Neurology 97(8):378\u2013388. https:\/\/doi.org\/10.1212\/WNL.0000000000012323","journal-title":"Neurology"},{"key":"13217_CR16","doi-asserted-by":"publisher","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med. 2025 May 15;392(19):1883\u20131892. https:\/\/doi.org\/10.1056\/NEJMoa2415988.","DOI":"10.1056\/NEJMoa2415988"},{"issue":"2","key":"13217_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"3","key":"13217_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/2013.jamaneurol.211","volume":"70","author":"E Erbayat Altay","year":"2013","unstructured":"Erbayat Altay E, Fisher E, Jones SE, Hara-Cleaver C, Lee JC, Rudick RA (2013) Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA Neurol 70(3):338\u2013344. https:\/\/doi.org\/10.1001\/2013.jamaneurol.211","journal-title":"JAMA Neurol"},{"issue":"11","key":"13217_CR19","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J M\u00fcller","year":"2023","unstructured":"M\u00fcller J, Cagol A, Lorscheider J, Tsagkas C, Benkert P, Yaldizli \u00d6, Kuhle J, Derfuss T, Sormani MP, Thompson A, Granziera C, Kappos L (2023) Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review. JAMA Neurol 80(11):1232\u20131245. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331","journal-title":"JAMA Neurol"},{"issue":"7154","key":"13217_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/bmj.317.7154.307","volume":"317","author":"CM Rembold","year":"1998","unstructured":"Rembold CM (1998) Number needed to screen: development of a statistic for disease screening. BMJ 317(7154):307\u2013312. https:\/\/doi.org\/10.1136\/bmj.317.7154.307","journal-title":"BMJ"},{"key":"13217_CR21","doi-asserted-by":"publisher","unstructured":"Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Barkhof F, Schoonheim MM, Strijbis EM, Vrenken H, Gallo A, Bisecco A, Ciccarelli O, Yiannakas M, Rovira A, Sastre-Garriga J, Palace J, Matthews L, Gass A, Eisele P, Lukas C, Bellenberg B, Margoni M, Preziosa P, Filippi M; MAGNIMS Study Group. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):10\u201318. https:\/\/doi.org\/10.1136\/jnnp-2022-329854.","DOI":"10.1136\/jnnp-2022-329854"},{"issue":"1","key":"13217_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/jnnp-2023-331799","volume":"95","author":"M Lauerer","year":"2023","unstructured":"Lauerer M, McGinnis J, Bussas M, El Husseini M, Pongratz V, Engl C, Wuschek A, Berthele A, Riederer I, Kirschke JS, Zimmer C, Hemmer B, M\u00fchlau M (2023) Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 95(1):37\u201343. https:\/\/doi.org\/10.1136\/jnnp-2023-331799","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13217_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102988","volume":"52","author":"NR Oksbjerg","year":"2021","unstructured":"Oksbjerg NR, Nielsen SD, Blinkenberg M, Magyari M, Sellebjerg F (2021) Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord 52:102988. https:\/\/doi.org\/10.1016\/j.msard.2021.102988","journal-title":"Mult Scler Relat Disord"},{"issue":"17","key":"13217_CR24","doi-asserted-by":"publisher","first-page":"175628642412777","DOI":"10.1177\/17562864241277736","volume":"8","author":"T Derfuss","year":"2024","unstructured":"Derfuss T, Bermel R, Lin CJ, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G, Hartung HP, Weber MS, Wang J, Jessop N, Chognot C, Craveiro L, Bar-Or A (2024) Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials. Ther Adv Neurol Disord 8(17):17562864241277736. https:\/\/doi.org\/10.1177\/17562864241277736","journal-title":"Ther Adv Neurol Disord"},{"issue":"14","key":"13217_CR25","doi-asserted-by":"publisher","first-page":"1277477","DOI":"10.3389\/fneur.2023.1277477","volume":"6","author":"KM Blok","year":"2023","unstructured":"Blok KM, van Rosmalen J, Tebayna N, Smolders J, Wokke B, de Beukelaar J (2023) Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis. Front Neurol 6(14):1277477. https:\/\/doi.org\/10.3389\/fneur.2023.1277477","journal-title":"Front Neurol"},{"key":"13217_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101892","volume":"39","author":"M Marrodan","year":"2020","unstructured":"Marrodan M, Bensi C, Pappolla A, Rojas JI, Gait\u00e1n MI, Ysrraelit MC, Negrotto L, Fiol MP, Patrucco L, Cristiano E, Farez MF, Correale J (2020) Disease activity impacts disability progression in primary progressive multiple sclerosis. Mult Scler Relat Disord 39:101892. https:\/\/doi.org\/10.1016\/j.msard.2019.101892","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"13217_CR27","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1111\/ene.14861","volume":"28","author":"G Mathey","year":"2021","unstructured":"Mathey G, Ancel T, Garot T, Soudant M, Pittion-Vouyovitch S, Guillemin F, Debouverie M, Epstein J (2021) Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort. Eur J Neurol 28(7):2238\u20132248. https:\/\/doi.org\/10.1111\/ene.14861","journal-title":"Eur J Neurol"},{"issue":"10","key":"13217_CR28","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1007\/s00415-024-12621-9","volume":"271","author":"CG Chisari","year":"2024","unstructured":"Chisari CG, Amato MP, Di Sapio A, Foschi M, Iaffaldano P, Inglese M, Fermo SL, Lugaresi A, Lus G, Mascoli N, Montepietra S, Pesci I, Quatrale R, Salemi G, Torri Clerici V, Totaro R, Valentino P, Filippi M, Patti F (2024) Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA). J Neurol 271(10):6801\u20136810. https:\/\/doi.org\/10.1007\/s00415-024-12621-9","journal-title":"J Neurol"},{"issue":"1","key":"13217_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26913","volume":"96","author":"M Calabrese","year":"2024","unstructured":"Calabrese M, Preziosa P, Scalfari A, Colato E, Marastoni D, Absinta M, Battaglini M, De Stefano N, Di Filippo M, Hametner S, Howell OW, Inglese M, Lassmann H, Martin R, Nicholas R, Reynolds R, Rocca MA, Tamanti A, Vercellino M, Villar LM, Filippi M, Magliozzi R (2024) Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol 96(1):1\u201320. https:\/\/doi.org\/10.1002\/ana.26913","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13217-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T06:26:05Z","timestamp":1752301565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13217-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["13217"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13217-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marco Vercellino has received congress grants, speaker fees and advisory board fees from Merck, Novartis, Roche, Biogen. Chiara Bosa has received speaker fees from Merck and Novartis, and congress grants from Biogen, Teva, Sanofi, Roche, Merck, Novartis, and Horizon. Stella Marasciulo, Paola Garelli, Anna Rolando, Maria Letizia Vassallo, Virginia Gallina, Giovanni Morana report no conflicts of interest. Paola Cavalla has received congress grants, speaker fees and advisory board fees from Alexion, Almirall, Biogen, Celgene-BMS, Merck-Serono, Teva, Roche, Novartis, Sanofi-Genzyme, Janssen and Horizon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"482"}}